Bexarotene Capsule, Liquid Filled
NDC Package 43975-315-10
Package Information
Bexarotene capsules is bexarotene is used to treat skin problems from a certain type of cancer (cutaneous T-cell lymphoma-CTCL). This formulation utilizes a capsule, liquid filled delivery system. Marketed by Ani Pharmaceuticals, Inc., this product is identified by NDC 43975-315 and is authorized under FDA application ANDA209861.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 43975 - Ani Pharmaceuticals, Inc.
- 43975-315 - Bexarotene
- 43975-315-10 - 100 CAPSULE, LIQUID FILLED in 1 BOTTLE
- 43975-315 - Bexarotene
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 43975-315-10 identifies a specific commercial package of 100 capsule, liquid filled in 1 bottle of Bexarotene, a human prescription drug labeled by Ani Pharmaceuticals, Inc.. This capsule, liquid filled is formulated for oral use and contains bexarotene as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ani Pharmaceuticals, Inc. on May 10, 2018. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Bexarotene is used to treat skin problems from a certain type of cancer (cutaneous T-cell lymphoma-CTCL). It belongs to a class of drugs called retinoids (vitamin A derivatives). Bexarotene works by slowing or stopping the growth of cells.
How is this Ani Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 43975031510. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.